 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Dec 08, 2022 |
| Title |
Anti-HIV-1 CAR-T cells armed with autogenic broadly neutralizing antibody and follicle-homing receptor CXCR5 ar effective against different HIV-1 clades and reduce viral reservoir in HIV-1-infected individuals |
| Organism |
Human immunodeficiency virus 1 |
| Experiment type |
Other
|
| Summary |
Chimeric antigen receptor T (CAR-T) cells, long proposed for HIV-1 treatment, has yet to achieve desirable therapeutic efficacy. In our study, M10 CAR-T cells were used for treating 18 HIV-1 patients via a regimen combining two M10 infusions and repeat chidamide stimulation for HIV reservoir activation. Consequently, 74.3% of M10 infusions resulted in significant suppression of viral rebound (averaging 77.4% decline), with 10 patients showing persistently reduced cell-associated HIV-1 RNA levels (averaging > 1.15 log10) over the 150-day observation period. To evaluate the genetic change, the PCR products were sequenced on a PacBio sequel platform by Genewiz (Genewiz, Suzhou, China) in 10 HIV patients treated by M10 CAR-T immunotherapy and 2 controls only applied with HAART therapy. High-throughput sequencing of partial pol gene and env gene amplified from whole blood samples at baseline or final visit.The results demonstrated that several participants showed a genetic shift in the composition of viral reservoir populations after treatment. Additionally, in some participants, the remaining proviruses showed reduced overall diversity in the virus pol gene. The results also reveal the selective pressure mainly targeted the env gene. This comprehensive survey supported the potential of M10 CAR-T cells as a new, safe, and effective therapeutic option toward HIV-1 eradication in AIDS patients.
|
| |
|
| Overall design |
M10 CAR-T cells were used for treating 18 HIV-1 patients via a regimen combining two M10 infusions and repeat chidamide stimulation for HIV reservoir activation.To evaluate the genetic change, the PCR products were sequenced on a PacBio sequel platform by Genewiz (Genewiz, Suzhou, China) in 10 HIV patients treated by M10 CAR-T immunotherapy and 2 controls only applied with HAART therapy.
Please note that the *.target.fa.gz contains 10nt of upstream and downstream of HIV protease/ reverse transcriptase (PR/RT) region extracted from the sequencing data . The files were included in the records as the study focuses on the diversity and genetic distance of this region in the sequencing analysis section, and to help other readers to reproduce the original data.
|
| |
|
| Contributor(s) |
Mao Y, Xu J |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| BioProject |
PRJNA903552 |
| |
| Submission date |
Dec 05, 2022 |
| Last update date |
Dec 10, 2022 |
| Contact name |
Zhu YouWei |
| E-mail(s) |
ywzhu22@m.fudan.edu.cn
|
| Phone |
19145632696
|
| Organization name |
Fudan university
|
| Department |
Institutes of Biomedical Sciences
|
| Street address |
130 Dong'an Road
|
| City |
上海 |
| State/province |
Shanghai |
| ZIP/Postal code |
200032 |
| Country |
China |
| |
|
| Platforms (2) |
| GPL32910 |
sequel II (Human immunodeficiency virus 1) |
| GPL32911 |
sequel (Human immunodeficiency virus 1) |
|
| Samples (26)
|
|
| Supplementary file |
Size |
Download |
File type/resource |
| GSE220111_RAW.tar |
33.4 Mb |
(http)(custom) |
TAR (of FA, TXT) |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data provided as supplementary file |
|
|
|
|
 |
Less...
More...